Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company focused on genetic treatments for neurological diseases, has unveiled new preclinical data on its Alzheimer’s disease therapies. With a market capitalization of $201.51 million, the company currently trades near its 52-week low of $3.56, according to InvestingPro data, which also indicates the stock may be undervalued based on its Fair Value analysis. The company presented findings on its tau silencing gene therapy, VY1706, and anti-tau antibody, VY7523, at the International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, which took place from April 1-5, 2025.
According to the data, a single intravenous dose of VY1706 in non-human primates led to a significant reduction in tau mRNA and protein levels across the brain, including regions affected by Alzheimer’s disease. This reduction was sustained for up to three months post-dosing. The therapy was well-tolerated and showed liver de-targeting, which could potentially minimize side effects. Voyager plans to file an Investigational New Drug application for VY1706 with the FDA in 2026.
In murine studies, the VY7523 antibody selectively targeted pathologic tau tangles, which are associated with Alzheimer’s disease progression. The murine version of VY7523, along with another third-party antibody, successfully reduced tau spread in a mouse model. Voyager is currently conducting a multiple ascending dose trial of VY7523 in early-stage Alzheimer’s patients, with initial tau positron emission tomography imaging data expected in the second half of 2026.
These findings suggest that Voyager’s tau-targeted therapies could potentially transform the treatment landscape for Alzheimer’s disease, a condition that affects millions worldwide and carries significant economic and social burdens. InvestingPro analysis shows that while the company maintains strong liquidity with a current ratio of 5.56 and holds more cash than debt, analysts expect sales to decline in the current year. Four analysts have recently revised their earnings expectations upward, with price targets ranging from $9 to $30.
Voyager will recap key data from the AD/PD™ 2025 conference in a live webcast on Monday, April 7, 2025. The event will provide further insights into the company’s research and development efforts.
Alzheimer’s disease remains a major challenge in healthcare, with current treatments only addressing symptoms rather than the underlying causes. Voyager’s advancements in tau-targeted therapies may offer new hope for patients and caregivers. The company continues to leverage its genetic platforms to develop treatments for various central nervous system diseases. Investors can access comprehensive analysis and 8 additional ProTips about Voyager Therapeutics through InvestingPro, including detailed financial health metrics and growth projections. The next earnings announcement is scheduled for May 13, 2025, which could provide further insights into the company’s development pipeline and financial outlook.
This report is based on a press release statement from Voyager Therapeutics, Inc.
In other recent news, Voyager Therapeutics has reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of -0.37, aligning with analysts’ expectations. However, the company did not disclose its revenue forecast. Despite the financial results, Voyager maintains a strong cash position of $332 million, with potential future milestone payments amounting to $8.2 billion, ensuring operational funding until mid-2027. Analysts from Canaccord Genuity and Citi have adjusted their price targets for Voyager, reducing them to $12.00 and $11.00, respectively, but both firms have maintained a Buy rating for the company. Truist Securities and H.C. Wainwright also continue to recommend a Buy rating, with price targets set at $18.00 and $30.00, respectively. Voyager’s strategic partnerships with companies like Neurocrine Biosciences, Novartis, and Alexion could yield significant milestone payments. The company is advancing its gene therapy programs, with upcoming data presentations expected at major conferences, such as the Alzheimer’s & Parkinson’s Disease Conference in 2025. These developments highlight Voyager Therapeutics’ ongoing efforts in the field of gene therapy for neurological diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.